CYP3A5 and benign prostatic hyperplasia: This study represents the first comprehensive investigation examining the effects of polymorphisms in CYP3A4*1B (c.-392G>A, rs2740574), CYP3A4*22 (c.522-191C>T, rs35599367), CYP3A5*3 (c.6986A>G, rs776746), UGT2B7 (rs73823859, rs7439366, and rs7668282), and ABCB1 (rs4148738, rs1045642, rs2032582, and rs1128503) on both the pharmacokinetics and clinical effects of silodosin in BPH patients.